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knowledge of the FDA-approved indications of commonly prescribed drugs, and to 
assess whether physicians’ belief that an indication is FDA-approved increases with
level of evidence supporting such use. METHODS: We conducted a national random 
sample mail survey of 599 primary care physicians and 600 psychiatrists conducted 
from November 2007 through August 2008. Physicians were presented with 14 drug-
indication pairs (e.g., gabapentin [Neurontin] for diabetic neuropathy) that varied
in their FDA-approval status and levels of supporting evidence. The main outcome
measure was physicians’ knowledge of whether each drug was FDA-approved for the
indication in question. RESULTS: The adjusted response rate was 47%, and the mean 
(median) number of drugs examined that were prescribed during the previous 12 
months was 11 (12). The average respondent correctly identiﬁ ed the FDA-approval
status of just over half of the drug-indication pairs queried (mean 55%; median 57%). 
The proportion increased modestly (mean 59%, median 61%) when limited to drugs
the respondent reported having prescribed during the previous 12 months. There was 
a strong association between physicians’ belief that an indication was FDA-approved
and greater evidence supporting that use (Spearman’s rho 0.74, p  0.001). However, 
41% of physicians believed at least one drug-indication pair with uncertain or no 
supporting evidence (e.g., quetiapine [Seroquel] for dementia with agitation) was 
FDA approved. CONCLUSIONS: These ﬁ ndings highlight an important need for 
more effective methods to inform physicians about the evidence base, or lack thereof, 
for drugs they prescribe off label.
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OBJECTIVES: Prescription charges were abolished in Wales in April 2007. We hypoth-
esised that as a result, the demand for prescription medicines might increase, and
compared the rates of dispensing of the 15 medicines that most frequently incurred a
prescription charge, versus a region with similar socio-economic characteristics that
continues to charge patients (NE England). METHODS: Monthly data from 2002 to
2008 (one year post abolition) on the quantities of dispensed medicines were obtained 
from Health Solutions Wales and the Prescription Pricing Authority. Descriptive com-
parative analyses of unadjusted dispensing rates (per 1000 list size) were conducted for 
each medicine. RESULTS: The combined dispensing rates for all 15 medicines increased 
signiﬁ cantly in both regions, but the change in Wales was higher than that in England 
(Wales change  57.67, p  0.0001, 95%CI  55.09 to 60.28; NE England change 
30.18, p  0.0001, 95%CI 27.32 to 33.03). The difference between regions was statisti-
cally signiﬁ cant (difference  27.51, p  0.0001, 95%CI 23.66 to 31.35). Whilst an 
expected widening of the difference between regions was apparent for some medicines,
factors beside the abolition of prescription charges are likely to account for the 
observed differences in others. For atenolol, a reduction in overall dispensing is
observed to coincide with trial evidence that cast doubts for its suitability as a ﬁ rst-line
drug for hypertension. The dispensing of co-codamol has risen dramatically in Wales, 
but not NE England, possibly related to different recommendations following the
withdrawal of co-proxamol. CONCLUSIONS: The abolition of prescription charges
is associated with changes in dispensing rates in Wales for some evaluated medicines.
However, the data require to be interpreted in the context of the low proportion of 
prescriptions that were previously charged, and changes in clinical practice.
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OBJECTIVES: To compare legislation on paediatric dosing guidelines and indications
between the US and Europe and to examine whether the introduction of new regula-
tions and ﬁ nancial incentives has resulted in more pharmaceutical companies provid-
ing paediatric data. METHODS: Information was extracted from published policies
and reports on paediatric therapeutics as published by the US Food and Drug Admin-
istration and the European Medicines Agency. RESULTS: In the US, the Food and
Drug Administration Modernisation Act (FDAMA; 1997) offered six months of mar-
keting exclusivity to manufacturers voluntarily conducting paediatric studies. Current 
legislation in the US consists of the Best Pharmaceuticals for Children Act (BPCA; 
2002), and the Paediatric Research Equity Act (PREA; 2003). Manufacturers are also
encouraged to obtain orphan drug designation for drugs or biological products for
use in a paediatric population. To January 2008, the FDA has sent written requests 
for paediatric studies to sponsors of 301 drugs. There have been 157 incidents of 
labeling changes under the BPCA and 76 labeling changes or submissions of support-
ing information under the PREA. Legislation on paediatric therapeutics was issued in
the EU in January 2007 (Regulation (EC) No 1901/2006 as amended). Since this time, 
the EMEA has adopted decisions on 99 applications for paediatric investigational 
plans (PIPs) and waivers; 57 positive opinions on PIPs; 3 proposed modiﬁ cations to
PIPs; and 39 waivers in all age groups for all conditions. Additionally, most European
Health Technology Assessment agencies do not make special allowances for the assess-
ment of paediatric therapeutics and dosing. CONCLUSIONS: The introduction of 
legislation in the US has been successful in encouraging research into the use of thera-
peutics in paediatric patients. In the EU, although many applications of PIPs and 
waivers have been reviewed, the situation should be monitored over the coming years 
to determine if the legislation leads to changes.
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OBJECTIVES: Across countries with varying political, socioeconomic and cultural 
environments, we sought to identify predictors of generic drug utilization. METHODS:
Data were collected from national and international regulatory agencies, MEDLINE
and internet searches for 37 countries classiﬁ ed as “advanced” or “emerging” econo-
mies by the International Monetary Fund: Argentina, Australia, Austria, Belgium, 
Brazil, Canada, China, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, 
India, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Mexico, Netherlands, New
Zealand, Norway, Portugal, Russia, San Marino, Singapore, Slovenia, South Korea, 
Spain, Sweden, Switzerland, Taiwan, UK, United States. We compared the presence
of generic policies, ﬁ rst year of generic legislation, branded drug patent duration, 
proportion of generic drug utilization, and pricing for generics (government control, 
free market, or other), gross domestic product, and population across countries. Only 
independent variables with p  0.20 in univariate regression were included in the 
multivariate model: population, year of generic legislation, patent life, and pricing for 
generics (market vs. government control). RESULTS: Of 37 countries, data was avail-
able for 26 (70%): Argentina, Australia, Austria, Brazil, Belgium, Canada, Denmark, 
Finland, France, Germany, Greece, Ireland, Italy, Japan, Mexico, Netherlands, New 
Zealand, Norway, Portugal, Russia, Singapore, Spain, Sweden, Switzerland, UK and 
United States. Most countries enacted generic drug legislation in the 1990s, 9 (35%) 
introduced legislation before 1990, and 3 (12%) after 2000. Branded drug patent
duration was 15–20 years for 65% of countries. Among countries with generic drug 
laws, only free market-based generic pricing, compared to government-controlled 
pricing, was associated with a nominal increase in generic drug utilization (B  0.17, 
95% CI 0.01, 0.35). CONCLUSIONS: Countries with free market pricing policies 
had minimally greater diffusion of generic drugs compared to countries with govern-
ment pricing controls. Further investigation of other characteristics, namely the politi-
cal and social climates that foster greater generic drug utilization is planned.
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OBJECTIVES: To compare socioeconomic and behavioral characteristics of Medicare 
Part-D enrollees who reached prescription drug coverage gap (in-gap) versus those 
who did not (no-gap), in 2007. The study is unique because it examined characteristics 
of Medicare Part-D enrollees that are typically not available in administrative claims 
databases. METHODS: A survey based on the Seniors’ Prescription Coverage, Use 
and Spending Survey and the Brief Medication Questionnaire was developed and dis-
tributed to elderly persons seeking care at the pharmacies within the University of 
Arkansas for Medical Sciences College of Pharmacy Advanced Community Practice 
Network. Patients recruited were 65 years or older, enrolled in Medicare Part D in
2007, and taking medications for any of the following conditions: hypertension, 
hyperlipidemia, diabetes, asthma/COPD, or depression. RESULTS: In this initial
phase, 69 patients were enrolled and 24 (34.8%) reported reaching the coverage gap
in 2007. Among in-gap patients, 95% were aged 65–85 years and 58% were female, 
compared to 73% and 64% respectively for the no-gap subjects. Compared with the
no-gap subjects, more in-gap subjects attended college (78% vs. 46%), had a monthly
income of $2000 or more (70.8% vs. 56%), and spent more than $300 per month
on medications (42% vs. 24%). Compared with no-gap patients, in-gap patients were 
less likely (54% vs. 69%) to report overall satisfaction with Part-D programs. Finally, 
87.5% of the in-gap patients reached the gap in September 2007 or later. CONCLU-
SIONS: One-third of the subjects reached the coverage gap and most of them reached 
the gap within the last quarter of 2007, mitigating the impact of coverage gap to some 
extent. The in-gap group belonged to higher socioeconomic status, which was expected
since the no-gap group appeared not to be at the risk of coverage gap because of 
low-income subsidies. Experiencing coverage gap negatively impacted patients’ satis-
faction with Part-D plans.
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OBJECTIVES: Taiwan’s National Health Insurance’s (NHI) generous coverage and 
patients’ freedom to access different tiers of medical facilities has resulted in accelerat-
ing outpatient care utilisation and cost. To deter non-essential visits and encourage 
initial contact in primary care, a differential co-payment was introduced on July 15, 
2005. Under this, patients pay more for outpatient consultations at higher medical
facilities, particularly if accessed without referral. This study aimed to explore the 
impact of this policy on outpatient medical activities and expenditure, different co-
payment groups and tiers of medical facilities. METHODS: A segmented time-series 
analysis on regional weekly outpatient medical claims (January 2004 to July 2006). 
Outcome variables (number of visits, number of outpatients, total cost of outpatient 
care) and variables for cost structure were stratiﬁ ed by tiers of medical facilities and 
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co-payment groups. Analysis used the auto-regressive integrated moving-average 
model in STATA 9.0. RESULTS: The overall number of outpatient visits signiﬁ cantly 
decreased after policy implementation due to a reduction in the number of patients 
using outpatient facilities, but total costs of care remained unchanged. The policy had 
its greatest impact on the number of visits to regional and local community hospitals 
(secondary), but had no inﬂ uence on those the medical centres (tertiary). Medical 
utilisation in physician clinics (primary) decreased due to an audit of reimbursement 
declarations. Overall, the policy failed to encourage referrals from primary care to 
higher tiers. CONCLUSIONS: Further research needs to explore how patients’ out-
of-pocket payment affects medical utilisation and which forces (not susceptible to co-
payment) act in tertiary facilities. It also needs to investigate, whether the reduction 
in outpatient numbers was due to an affordability barrier to accessing essential care, 
with a potentially negative impact on the region’s health.
PHP12
HOW NON-REFERRAL OUTPATIENT CO-PAYMENT IN TAIWAN IMPACTS
ON PATIENTS’ OUT-OF-POCKET COSTS AND PRESCRIPTION PATTERNS
Chen LC1, Schafheutle E2, Noyce P2, Wen YH1, Wu JS3
1Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2University of Manchester, 
Manchester, UK, 3Bureau of National Health Insurance, Kaohsiung, Taiwan
OBJECTIVES: To deter non-essential visits and encourage initial contact in primary
care, Taiwan’s National Health Insurance’s (NHI) implemented a differential co-
payment policy on July 15, 2005. A previous study has examined the impact of this
policy on medical utilization and total cost to NHI using a regional reimbursement 
dataset. This study aimed to explore the impact of this policy on outpatient co-
payment and prescription patterns across different co-payment groups and tiers of 
medical facilities. METHODS: A segmented time-series analysis on regional weekly 
outpatient medical claims (January 2004 to July 2006). Outcome variables for co-
payment and prescription patterns were stratiﬁ ed by tiers of medical facilities and co-
payment groups. Analysis used the auto-regressive integrated moving-average model 
in STATA 9.0. RESULTS: Despite the decrease in outpatient visits, the overall co-
payment to patients increased by 1.2% after policy implementation and also increased
in most medical facilities (4.8% to 17.9%). Number of general prescriptions decreased 
across different medical facilities; the average cost and duration per general prescrip-
tion decreased in medical centers and regional hospitals. The number of continuous 
prescriptions did not change, except for non-signiﬁ cant decreases in medical centers
and regional hospitals. There was an increase in the number of continuous prescrip-
tions dispensed in pharmacies (7.0%). CONCLUSIONS: The police signiﬁ cantly 
increased patients’ out-of-pocket payment for outpatient visits. In response to the 
policy, physicians might prescribe more expensive drugs and extend prescription dura-
tion to help patients get the most beneﬁ t from the co-payment, and physician in
medical centers are more likely to prescribe continuous prescriptions for patients with
stable chronic diseases. Further research needs to identify vulnerable subgroups in 
obtaining necessary treatment, and to explore the impacts of cost-saving strategies on 
patients’ quality of medical care.
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OBJECTIVES: We sought to evaluate the impact of pharmacy cost-containment policy 
actions by state Medicaid programs on cost-related underuse of medicine, controlling
for concurrent non-pharmacy cost-containment policy actions and socio-environmen-
tal differences among states. METHODS: We used the data from the 2003 Community
Tracking Study (CTS) household survey, and linked them with the census demographic 
data and the cost containment policy actions based upon 50 States Surveys on state 
Medicaid spending growth and cost containment policy actions by the Kaiser Family
Foundation in 2003. A cross-sectional study was performed to evaluate the impact of 
policy actions, by comparing Medicaid beneﬁ ciaries to non-Medicaid-pharmacy-cost-
containment-action-eligible residents. The outcome measures included: patients do not 
receive needed medical care, patients cannot afford needed prescriptions, patients
postpone needed medical care, and patients worry about the medical care cost. The 
outcomes were analyzed using logit model, with prior authorization, generic drugs
required, copayment method, step therapy of fail-ﬁ rst requirement, limit on number 
of prescriptions and number of reﬁ lls per month, preferred drug list, over the counter
coverage, and prescription drug payment practices (payment and purchasing policies) 
as predictors. Additionally, non-pharmacy cost-containment policy actions, patients’
demographics and states’ socio-environmental variables were controlled. RESULTS:
On average, each state has implemented 6.5% pharmacy cost containment policy
actions in 2003. Only the worrying about costs was statistically signiﬁ cantly associated
with individual pharmacy cost-containment policy action; however, such signiﬁ cance
disappeared after other concurrent pharmacy cost-containment policy actions were
controlled for. When the total number of pharmacy cost-containment policy actions
was entered in the regression instead of individual policy action, each incremental 
policy action was associated with 14% increase in odds ratio for unmet medical needs
(p  0.003), and 5% increase in odds ratio for postponing medical needs (p  0.02). 
CONCLUSIONS: There was variable impact of pharmacy cost-containment policy
actions when assessed concurrently, and collectively.
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OBJECTIVES: Although cost-effectiveness analysis allows efﬁ cient decisions about the 
use of existing technologies (static efﬁ ciency) it has been argued that it will disincen-
tivise the development of innovative technologies (dynamic efﬁ ciency). These concerns
have also been raised about the report by the UK Ofﬁ ce of Fair Trading which recom-
mended that the price of pharmaceuticals should be based on their cost-effectiveness. 
We aim to establish whether decisions based on cost-effectiveness necessarily under-
mine incentives for the development of pharmaceuticals. METHODS: The arguments
put forward as to why cost-effectiveness decisions might undermine incentives for
innovation are examined and are used to consider the implications of the type of 
value-based pricing which has been proposed in the UK. RESULTS: The argument 
depends on whether the purpose of health care is to improve population health or to 
maximise welfare (consumer and producer surplus). If it is the former, then achieving
static and dynamic efﬁ ciency requires a clear and predictable signal of value (cost-
effectiveness). The private sector can then choose to invest in developments which it 
believes will be cost-effective and provide a satisfactory return on investment. Manu-
facturers should be allowed to appropriate some share of the surplus (monopoly rent) 
to incentivise investment in R&D. However, they should not take it all. The public 
sector subsidises research and development in many ways. Therefore, even if society
was unconcerned about who beneﬁ ts from innovation it would not be efﬁ cient to
allow full appropriation. In other markets where innovation is protected, society 
simply offers monopoly rent during patent protection but does not allow full appro-
priation by, for example, facilitating perfect price discrimination. CONCLUSIONS:
The argument that decisions about the use and price of a technology based on cost-
effectiveness will undermine the incentives for R&D is misplaced if the objective is to 
improve population health given a ﬁ xed budget constraint.
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OBJECTIVES: The Orphan Drug Act (ODA) was developed in 1983 to stimulate new
drug development to treat rare diseases. The purpose of this analysis was to review
the drug development with orphan drug status and to describe utilization of orphan 
drugs in the Medicaid program. METHODS: A literature review about orphan drug 
approvals was conducted through search engine like PubMed, as well as government
and industry Internet websites. Nationwide Medicaid pharmacy data extracted from
the Center for Medicare & Medicaid Services were analyzed from 1991 to 2007 
regarding quarterly prescriptions, reimbursements, and cost per prescription for
selected orphan drugs. Based on utilization patterns, two categories of orphan drugs
were studied, including traditional ones with little use (like antizole, fabrazyme, 
respigam, myozyme, and panhematin) and non-traditional ones with wide usages (like
paclitaxel, epoetin alfa, and imatinib mesylate). RESULTS: Since 1983, over 1700
drugs have been designated as having orphan status and 325 drugs have marketing
approval to treat orphan diseases, focusing on oncology, metabolic and endocrine 
disorders, and hematology. From Medicaid pharmacy data, there was very little use
for antizole, respigam, myozyme, and other traditional orphan drugs, such as fabra-
zyme from 15 in 2003 to the peak of 375 in 2006. By contrast, non-traditional orphan 
drug like epoetin alfa prescriptions increased from 17,282 in 1991 to the peak of 
824,485 in 2005, and imatinib mesylate prescriptions increased from 3,877 in 2001
to the peak of 20,323 in 2005. Fabrazyme cost per prescription started with $22,367
in 2003 and decreased to $5,558 in 2006. Other expensive orphan drugs included
myozyme, panhematin, imatinib mesylate, and ritumximab ranging from $3,000 to 
$10,000 per prescription. CONCLUSIONS: ODA has made a signiﬁ cant impact on
drug development for rare diseases. Non-traditional orphan drugs with dramatic 
increased utilization and spending were observed, which might require safety surveil-
lance and appropriate utilization review.
PHP16
MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE
UNITED STATES: ANALYSIS OF DRUGS APPROVED BY THE FDA
FROM 1939 TO 2008
Qureshi ZP1, Szeinbach SL1, Seoane-Vazquez E1, Rodriguez-Monguio R2
1Ohio State University, Columbus, OH, USA, 2University of Massachusetts, Amherst, Amherst, 
MA, USA
OBJECTIVES: The pharmaceutical industry serves societal needs by bringing innova-
tive products and therapies to market. However, innovation does not guarantee 
market longevity. Consequently, some products will be evaluated and considered for 
market discontinuation. The purpose of this study was to identify drug market dis-
continuations, provide reasons for discontinuation, and characterize discontinued 
products by application type. METHODS: Data were derived from the FDA databases 
“Approved Drug Products” and the “Approved Drug Products with Therapeutic 
Equivalence Evaluations,” Federal Register, and Medline. Market discontinuations 
were classiﬁ ed by approval types (New Drug Application -NDA and Abbreviated New 
Drug Application-ANDA) and by reasons for discontinuation (safety, efﬁ cacy and 
